198 related articles for article (PubMed ID: 20673824)
1. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up.
Dubischar-Kastner K; Kaltenboeck A; Klingler A; Jilma B; Schuller E
Vaccine; 2010 Sep; 28(39):6463-9. PubMed ID: 20673824
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).
Schuller E; Klingler A; Dubischar-Kastner K; Dewasthaly S; Müller Z
Vaccine; 2011 Nov; 29(47):8669-76. PubMed ID: 21907747
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO
Jelinek T; Cromer MA; Cramer JP; Mills DJ; Lessans K; Gherardin AW; Barnett ED; Hagmann SHF; Askling HH; Kiermayr S; Kadlecek V; Eder-Lingelbach S; Taucher C; Dubischar KL
Travel Med Infect Dis; 2018; 22():18-24. PubMed ID: 29549036
[TBL] [Abstract][Full Text] [Related]
4. Product review on the JE vaccine IXIARO.
Firbas C; Jilma B
Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A
J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481
[TBL] [Abstract][Full Text] [Related]
6. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):661-3. PubMed ID: 21617632
[TBL] [Abstract][Full Text] [Related]
8. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.
Schuller E; Jilma B; Voicu V; Golor G; Kollaritsch H; Kaltenböck A; Klade C; Tauber E
Vaccine; 2008 Aug; 26(34):4382-6. PubMed ID: 18599165
[TBL] [Abstract][Full Text] [Related]
9. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.
Rabe IB; Miller ER; Fischer M; Hills SL
Vaccine; 2015 Jan; 33(5):708-12. PubMed ID: 25498208
[TBL] [Abstract][Full Text] [Related]
10. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
Erra EO; Kantele A
Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
[TBL] [Abstract][Full Text] [Related]
11. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
Cramer JP; Dubischar K; Eder S; Burchard GD; Jelinek T; Jilma B; Kollaritsch H; Reisinger E; Westritschnig K
Vaccine; 2016 Aug; 34(38):4579-4585. PubMed ID: 27460550
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.
Kaltenböck A; Dubischar-Kastner K; Schuller E; Datla M; Klade CS; Kishore TS
Vaccine; 2010 Jan; 28(3):834-9. PubMed ID: 19857447
[TBL] [Abstract][Full Text] [Related]
14. Ixiaro: a new vaccine against Japanese encephalitis.
Jelinek T
Expert Rev Vaccines; 2009 Nov; 8(11):1501-11. PubMed ID: 19863241
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.
Dubischar-Kastner K; Eder S; Buerger V; Gartner-Woelfl G; Kaltenboeck A; Schuller E; Tauber E; Klade C
Vaccine; 2010 Jul; 28(32):5197-202. PubMed ID: 20541581
[TBL] [Abstract][Full Text] [Related]
16. IC51 Japanese encephalitis vaccine.
Kollaritsch H; Paulke-Korinek M; Dubischar-Kastner K
Expert Opin Biol Ther; 2009 Jul; 9(7):921-31. PubMed ID: 19527110
[TBL] [Abstract][Full Text] [Related]
17. Update on Japanese encephalitis vaccine for children: United States, May 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):664-5. PubMed ID: 21617633
[TBL] [Abstract][Full Text] [Related]
18. Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO
Amicizia D; Zangrillo F; Lai PL; Iovine M; Panatto D
J Prev Med Hyg; 2018 Mar; 59(1):E99-E107. PubMed ID: 29938245
[TBL] [Abstract][Full Text] [Related]
19. A new inactivated Japanese encephalitis vaccine for adult travelers.
Toovey S
Travel Med Infect Dis; 2009 Sep; 7(5):301-4. PubMed ID: 19747666
[TBL] [Abstract][Full Text] [Related]
20. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
